The dog medication making headlines is Librela, a monthly injection approved by the FDA in May 2023 to treat osteoarthritis pain in dogs. It works by blocking nerve growth factor, a protein that amplifies pain signals in arthritic joints. While scattered social media posts have fueled curiosity about whether people are actually injecting themselves with this veterinary drug, the real story is both less dramatic and more concerning. No verified trend exists of humans self-injecting Librela.
The drug is a canine-specific antibody that carries explicit warnings against human use, including risks of anaphylaxis for pregnant or breastfeeding women who accidentally self-inject. What is actually happening, and has been documented by the veterinary community for years, is something different entirely. The genuine crossover between animal and human pain medication involves drugs like gabapentin, an FDA-approved human anticonvulsant that veterinarians prescribe off-label for dogs, and a well-documented pattern of people obtaining veterinary-prescribed opioids and controlled substances for personal use. Meanwhile, the human equivalent of Librela, a drug called tanezumab, was rejected by both the FDA and European regulators over alarming safety signals including accelerated joint destruction. This article breaks down what Librela actually is, why the human version failed, which veterinary drugs people genuinely do use, and what the risks look like for older adults already managing chronic pain alongside cognitive decline.
Table of Contents
- What Is the Dog Pain Medication That Has People So Curious?
- Why the Human Version of This Drug Was Rejected by Regulators
- The Drugs That Actually Cross Between Veterinary and Human Medicine
- Vet Shopping and the Hidden Opioid Pipeline
- Why Self-Medicating with Veterinary Drugs Poses Special Risks for Older Adults
- What Dementia Caregivers Should Know About Pain Management Options
- The Future of Anti-NGF Pain Treatment in Humans
- Conclusion
- Frequently Asked Questions
What Is the Dog Pain Medication That Has People So Curious?
Librela, manufactured by Zoetis, is the first monoclonal antibody approved by the FDA specifically for controlling osteoarthritis pain in dogs. Unlike traditional painkillers that mask symptoms broadly, Librela targets a single protein called nerve growth factor. NGF levels are elevated in dogs with osteoarthritis, and by binding to and neutralizing this protein, the drug interrupts a key pain signaling pathway. It is administered as a once-monthly subcutaneous injection at the veterinary clinic, not dispensed as a take-home pill. The drug attracted widespread attention partly because it represented a genuinely new approach to pain management, one that the human pharmaceutical industry had been chasing for over a decade without success. For dog owners watching their arthritic pets suddenly move with less pain, the logic was intuitive and tempting: if it works this well for my dog, why can’t I have it? But Librela is a one hundred percent canine antibody. It was engineered for the dog immune system, not the human one.
Injecting it into a person would at best do nothing useful and at worst trigger a severe immune reaction. The FDA label is unambiguous: not for use in humans. Even in the species it was designed for, Librela’s safety record has raised serious questions. The FDA has logged over eight thousand adverse event reports since the drug’s approval in May 2023. A 2025 study published in Frontiers in Veterinary Science found that ligament and tendon injuries, polyarthritis, fractures, and musculoskeletal neoplasia were reported approximately nine times more frequently in dogs treated with Librela than in dogs receiving comparator drugs. Zoetis issued a U.S. label update in 2025 reflecting this new safety data. For anyone considering a veterinary drug for personal use, the fact that it is generating concern even within its approved population should give serious pause.
Why the Human Version of This Drug Was Rejected by Regulators
The concept behind Librela was not born in veterinary medicine. Pharmaceutical companies had been developing anti-NGF drugs for human pain for years before the canine version reached the market. The most advanced human candidate was tanezumab, a humanized monoclonal antibody jointly developed by Pfizer and Eli Lilly that targeted the same nerve growth factor pathway. It was designed for people with osteoarthritis and chronic pain who had run out of good options. Tanezumab made it all the way to an FDA advisory committee review in March 2021. The committee voted nineteen to one against approval. The reason was not that the drug failed to reduce pain. It did reduce pain modestly.
The problem was what it did to joints in the process. Patients treated with tanezumab showed increased rates of rapidly progressive osteoarthritis, a condition where the joint essentially collapses at an accelerated pace. They also experienced subchondral insufficiency fractures and higher rates of total joint replacement compared to those on placebo. The European Medicines Agency independently refused marketing authorization in September 2021 for the same reasons. This is a critical point for older adults, particularly those managing both chronic pain and cognitive decline. A drug that dulls pain while silently accelerating the destruction of weight-bearing joints is especially dangerous for someone whose awareness of their own body may already be compromised by dementia. As of early 2026, no anti-NGF drug has been approved for human use anywhere in the world. The mechanism that makes Librela work in dogs proved too risky when applied to human biology, where the consequences of masking structural joint damage are far more severe.
The Drugs That Actually Cross Between Veterinary and Human Medicine
The real crossover story is not about experimental antibodies. It is about gabapentin. Originally developed and FDA-approved as a human anticonvulsant, gabapentin is now one of the most commonly prescribed medications in veterinary practice for pain, anxiety, and seizures in dogs. It is the same active compound in both settings. A person taking gabapentin prescribed by their neurologist and a dog taking gabapentin prescribed by their veterinarian are consuming the same drug. There is one important caveat. Some human liquid formulations of gabapentin contain xylitol, an artificial sweetener that is safe for people but potentially lethal to dogs.
Veterinary formulations are specifically made without xylitol. This distinction matters because it highlights how the same molecule can be packaged very differently depending on the intended species. But the pharmacology is identical. Gabapentin is widely prescribed in older adults for neuropathic pain, and many families caring for both an aging parent and an aging dog may have encountered the same drug name on two very different prescription labels. This shared pharmacology is not unusual. Many medications used in veterinary medicine, including certain antibiotics, anti-inflammatories, and antifungals, are the same compounds used in human medicine. The difference lies in dosing, formulation, and regulatory oversight, not in the fundamental chemistry.
Vet Shopping and the Hidden Opioid Pipeline
A more troubling dimension of the human-veterinary drug overlap involves controlled substances. The veterinary community has documented a practice known as vet shopping, where individuals visit multiple veterinary clinics to obtain opioids and other controlled medications ostensibly prescribed for their pets but intended for personal use. The drugs most commonly obtained this way include tramadol, Valium, Xanax, buprenorphine, and phenobarbital. This pipeline exists in part because of the Animal Medicinal Drug Use Clarification Act of 1994, known as AMDUCA, which permits veterinarians to use human-approved drugs in animals on an extra-label basis. This means veterinary clinics stock and dispense a wide range of controlled substances.
The top three opioids used in veterinary practice are buprenorphine, tramadol, and butorphanol, in that order. As human prescribers have tightened opioid access in response to the overdose crisis, some individuals have turned to veterinary channels as an alternative source. For families dealing with dementia care, this issue carries particular weight. Caregivers managing their own chronic pain while shouldering the physical demands of caring for someone with cognitive decline are under enormous strain. The temptation to use accessible medications, whether leftover veterinary prescriptions or drugs obtained through less-than-straightforward means, can be real. But veterinary-dispensed controlled substances carry the same addiction risks and drug interaction concerns as their human-prescribed equivalents, without the benefit of a physician monitoring for cognitive side effects or dangerous combinations with existing medications.
Why Self-Medicating with Veterinary Drugs Poses Special Risks for Older Adults
The risks of using veterinary medications without proper medical supervision are amplified for older adults and especially for those with any degree of cognitive impairment. Dosing is the first concern. Veterinary formulations are calibrated for species with dramatically different metabolisms, body compositions, and organ function. Even when the active ingredient is identical to a human drug, the concentration, inactive ingredients, and recommended dosing schedule may be entirely wrong for a person. Drug interactions represent a second and potentially more dangerous layer of risk. Older adults typically take multiple medications simultaneously.
Adding a veterinary-sourced drug without a physician’s knowledge means no one is screening for interactions with blood thinners, blood pressure medications, cholinesterase inhibitors used in dementia treatment, or the many other drugs common in geriatric polypharmacy. Gabapentin alone, when combined with opioids, significantly increases the risk of respiratory depression, a leading cause of overdose death. A caregiver or older adult self-dosing without professional oversight has no safety net. There is also the issue of contamination and quality control. While veterinary pharmaceuticals are manufactured under regulatory oversight, the supply chain and storage conditions are optimized for animal use. Compounded veterinary preparations in particular may not meet the same standards as drugs dispensed by a human pharmacy. For someone whose liver and kidney function may already be declining with age, even small differences in drug purity or potency can have outsized consequences.
What Dementia Caregivers Should Know About Pain Management Options
Pain is chronically undertreated in people with dementia, partly because cognitive decline makes it harder to report symptoms and partly because caregivers and clinicians may mistake pain-related agitation for behavioral symptoms of the disease itself. This undertreatment can drive desperate searches for relief, including unconventional sources. If a caregiver notices that a loved one’s veterinary pain medication seems to work well, the leap to wondering whether it might help a person is understandable even if it is medically inadvisable.
The better path is to work with a geriatrician or pain specialist who understands the intersection of chronic pain and cognitive impairment. Non-opioid options including certain antidepressants, topical anti-inflammatories, nerve blocks, and physical therapy have evidence behind them and carry fewer cognitive side effects than systemic painkillers. No one should feel that a veterinary pharmacy is their best remaining option for managing pain, but reaching that point is a signal that the current medical team needs to hear what is not working.
The Future of Anti-NGF Pain Treatment in Humans
Despite tanezumab’s failure, the anti-NGF approach has not been entirely abandoned by pharmaceutical researchers. The mechanism clearly works to reduce pain. The challenge is doing so without accelerating joint damage, and several theories exist about why the early trials produced such alarming orthopedic side effects. Some researchers believe the problem was dosing, others suspect that combining anti-NGF drugs with NSAIDs worsened outcomes, and still others think the issue is more fundamental to how NGF functions in maintaining joint integrity.
Whether a safer anti-NGF drug eventually reaches the human market remains uncertain. For now, the gap between what Librela can do for a dog and what is available for a person with osteoarthritis pain remains wide. Watching that space is reasonable. Reaching into the veterinary medicine cabinet is not.
Conclusion
The dog medication generating buzz is Librela, an anti-NGF monoclonal antibody that works well for canine osteoarthritis pain but was never designed for human biology. The human equivalent, tanezumab, was rejected by regulators on both sides of the Atlantic because it accelerated joint destruction. No anti-NGF drug is approved for people.
The genuine veterinary-to-human drug crossover involves gabapentin and, more troublingly, controlled substances obtained through vet shopping, a documented problem that parallels broader patterns in the opioid crisis. For older adults managing pain alongside cognitive decline, the risks of self-medicating with veterinary drugs are compounded by polypharmacy, altered metabolism, and the absence of physician oversight. Undertreated pain in dementia is a real and serious problem, but the answer lies in better communication with medical providers and exploration of evidence-based alternatives, not in repurposing medications formulated for a different species. If current pain management is not working, that is a conversation to have with a doctor, not a problem to solve at the veterinary clinic.
Frequently Asked Questions
Can humans safely take Librela, the dog arthritis injection?
No. Librela is a canine-specific monoclonal antibody. It is not formulated for the human immune system and carries risks of severe allergic reactions including anaphylaxis. The FDA label explicitly states it is for use in dogs only.
Why was the human version of Librela rejected by the FDA?
Tanezumab, the human anti-NGF antibody, was voted down nineteen to one by an FDA advisory committee in 2021. While it modestly reduced pain, it caused rapidly progressive osteoarthritis, subchondral insufficiency fractures, and increased rates of joint replacement surgery. The European Medicines Agency also refused approval.
Is gabapentin the same drug for humans and dogs?
Yes, gabapentin is the same active compound in both human and veterinary medicine. However, some human liquid formulations contain xylitol, which is toxic to dogs. The pharmacology is identical, but formulations differ.
What is vet shopping?
Vet shopping is a documented practice where individuals visit multiple veterinary clinics to obtain controlled substances such as tramadol, Valium, or buprenorphine that are prescribed for pets but intended for personal use. It has been flagged as a concern by the veterinary community.
Are there any anti-NGF pain drugs approved for humans as of 2026?
No. As of early 2026, no anti-NGF drug has received regulatory approval for human use in any country. Research continues but no candidates are close to market.
What should dementia caregivers do if pain is not being adequately managed?
Speak with a geriatrician or pain specialist about alternatives including topical anti-inflammatories, certain antidepressants with pain-modulating effects, nerve blocks, and physical therapy. Undertreated pain in dementia is common and often mistaken for behavioral symptoms of the disease.
